Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07336147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

StatusRecruiting
PhasePhase 2
Started2025-12-22
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 22, 2027 → Jun 22, 2028
See other at-risk trials from Chang Gung Memorial Hospital

Amendment history

2026-08-14
Study Status, Sponsor/Collaborators, Arms and Interventions v2
Primary completion pushed: 2027-12-22 → 2028-06-22
Collaborators+36 characters
Taiwanese Gynecologic Oncology Group
2026-01-12
Study Status, Eligibility v1
Re-verified, no change to tracked fields
2026-01-02
Original filing
Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC
Trial Details
NCT Number NCT07336147
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: Taiwanese Gynecologic Oncology Group
Conditions Female
Enrollment 45 participants
Start Date 2025-12-22
Primary Completion 2028-06-22 (estimated)
Study Completion 2030-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-17